Literature DB >> 11561155

Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins.

S W Hiebert1, B Lutterbach, J Amann.   

Abstract

The t(8;21), t(16;21), inv(16), and t(12;21) are some of the most frequent chromosomal translocations found in acute myeloid and acute lymphoblastic leukemia. The fusion proteins created by these chromosomal translocations are transcriptional repressors. A full understanding of the types of proteins that these fusion proteins recruit to repress transcription will not only clarify understanding of the molecular mechanism of action of these fusion proteins but also provide further targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561155     DOI: 10.1097/00062752-200107000-00003

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  15 in total

1.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Building multifunctionality into a complex containing master regulators of hematopoiesis.

Authors:  Tohru Fujiwara; Hsiang-Ying Lee; Rajendran Sanalkumar; Emery H Bresnick
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

3.  Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.

Authors:  Karina Barseguian; Bart Lutterbach; Scott W Hiebert; Jeffrey Nickerson; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

4.  TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a.

Authors:  Christofer Diakos; Sheng Zhong; Yuanyuan Xiao; Mi Zhou; Gisele M Vasconcelos; Gerd Krapf; Ru-Fang Yeh; Shichun Zheng; Michelle Kang; John K Wiencke; Maria S Pombo-de-Oliveira; Renate Panzer-Grümayer; Joseph L Wiemels
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

5.  Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype.

Authors:  Diana Vradii; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

6.  Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.

Authors:  Olatoyosi M Odenike; Serhan Alkan; Dorie Sher; John E Godwin; Dezheng Huo; Stephen J Brandt; Margaret Green; Jingping Xie; Yanming Zhang; David H Vesole; Patrick Stiff; John Wright; Richard A Larson; Wendy Stock
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.

Authors:  Jay L Grisolano; Julie O'Neal; Jennifer Cain; Michael H Tomasson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-24       Impact factor: 11.205

8.  Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.

Authors:  Robert Hines; Anita Boyapati; Dong-Er Zhang
Journal:  Blood Cells Mol Dis       Date:  2007-06-21       Impact factor: 3.039

9.  Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.

Authors:  Sayyed K Zaidi; Christopher R Dowdy; Andre J van Wijnen; Jane B Lian; Azra Raza; Janet L Stein; Carlo M Croce; Gary S Stein
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

10.  The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Authors:  Kristie L Durst; Bart Lutterbach; Tanawan Kummalue; Alan D Friedman; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.